Biogen Backs Down From M&A
Scangos says the firm will keep its head down to continue controlling costs, maximizing revenues and advancing the pipeline this year.
Scangos says the firm will keep its head down to continue controlling costs, maximizing revenues and advancing the pipeline this year.